NCT06338514 The Effectiveness of Dry Needling Treatment in Patients Diagnosed With Dorsal Myofascial Pain Syndrome.
| NCT ID | NCT06338514 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Kutahya Health Sciences University |
| Condition | Myofascial Trigger Point Pain |
| Study Type | INTERVENTIONAL |
| Enrollment | 50 participants |
| Start Date | 2024-04-25 |
| Primary Completion | 2026-10-10 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 50 participants in total. It began in 2024-04-25 with a primary completion date of 2026-10-10.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Back pain is commonly seen in the working-age population, with the peak occurrence around the age of 40. Its frequency does not increase with age and is not associated with age-related degenerative changes in the spine. Especially when the underlying cause is conditions such as myofascial pain syndrome (MPS), where regional muscle sensitivity in the rhomboid and trapezius areas is prominent, dry needling treatment has become increasingly popular and the subject of numerous studies in recent years. In the diagnosis of MPS, two valuable findings include the detection of a taut band upon palpation and the presence of trigger points in muscle fibers with mild finger pressure. The study we are planning involves a double-blind efficacy trial where real and sham dry needling procedures will be performed under ultrasound guidance, ensuring that both the patient and the evaluator are blinded. This study design has the potential to make a significant contribution to the literature in this field.
Eligibility Criteria
Inclusion Criteria: * Clinically diagnosed with Dorsal Myofascial Pain Syndrome associated with rhomboid and trapezius trigger point. * Having a shoulder pain Visual Analog Scale (VAS) score of 6 or higher. * Ability to read and write Exclusion Criteria: * History of spinal surgery. * Lesions, atrophy, or scars in the skin around the back. * Undergoing physiotherapy targeting the back and lumbar region in the last 6 months. * Undergoing an interventional procedure for back or lumbar pain in the last 3 months. * Use of steroids in the last 1 month. * Special conditions such as epilepsy, pregnancy, injection phobia, etc. * Inability to comply with the restriction on the use of steroid and non-steroidal anti-inflammatory drugs during the treatment period.
Contact & Investigator
Hasan H Gökpınar, Ass. Prof.
PRINCIPAL INVESTIGATOR
Kutahya Health Sciences University
Frequently Asked Questions
Who can join the NCT06338514 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 80 Years, studying Myofascial Trigger Point Pain. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06338514 currently recruiting?
Yes, NCT06338514 is actively recruiting participants. Contact the research team at hasanhuseyin.gokpinar@ksbu.edu.tr for enrollment information.
Where is the NCT06338514 trial being conducted?
This trial is being conducted at Kütahya, Turkey (Türkiye).
Who is sponsoring the NCT06338514 clinical trial?
NCT06338514 is sponsored by Kutahya Health Sciences University. The principal investigator is Hasan H Gökpınar, Ass. Prof. at Kutahya Health Sciences University. The trial plans to enroll 50 participants.